Tech Company Financing Transactions
Cedilla Therapeutics Funding Round
Cedilla Therapeutics secured a $56.2 million Series A venture capital round on 4/25/2018. Backers included Third Rock Ventures.
Transaction Overview
Company Name
Announced On
4/25/2018
Transaction Type
Venture Equity
Amount
$56,200,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
245 1st St. 3rd Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla's integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alexandra Glucksmann
Chief Scientific Officer
Brian Jones
Vice President
Delphine Collin
Vice President
Josh Murtie
Vice President
Eric Schwartz
VP - Bus. Development
Véronique Riethuisen
VP - Finance
Christopher Lindblom
VP - Human Resources
Justin Birtz
Browse more venture capital transactions:
Prev: 4/25/2018: Extend venture capital transaction
Next: 4/25/2018: Conversica venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record tech company VC transactions. All VC database entries on this site are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs